...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BioMed research international >Development of a 2-Plex Luminex-Based Competitive Immunoassay to Quantify Neutralizing Antibodies Induced by Virus-Like Particles for Human Papillomavirus 16 and 18
【24h】

Development of a 2-Plex Luminex-Based Competitive Immunoassay to Quantify Neutralizing Antibodies Induced by Virus-Like Particles for Human Papillomavirus 16 and 18

机译：2基于Luminex的竞争性免疫分析技术的发展，以量化人乳头瘤病毒16和18的病毒样颗粒诱导的中和抗体。

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Human papillomavirus (HPV) L1 virus-like particles (VLPs) were proven an effective vaccine candidate to prevent against HPV-16 and -18 infections. In order to evaluate the potency of our produced HPV-16 and -18 L1 VLPs-based vaccine candidates, also to quantify neutralizing antibodies induced by them, a 2-plex Luminex-based competitive immunoassay was developed. Unlike the published paper, the no-biotin conjugated neutralizing mAbs spiked normal human serum (NHS) was used for standard curve preparation, while phycoerythrin (PE) was not labeled directly to neutralizing mAbs for signaling. After the coupling optimization of VLPs to microspheres and the neutralizing mAbs biotinylation, the 2-plex standard curve was prepared with good fit and high dynamic range. In addition, no cross-reactivity was also confirmed. The 2-plex Luminex-based immunoassay represents good potential not only for vaccine candidate's evaluation but also for its further clinical use.
机译：人乳头瘤病毒（HPV）L1病毒样颗粒（VLP）被证明是预防HPV-16和-18感染的有效疫苗候选者。为了评估我们生产的基于HPV-16和-18 L1 VLPs的候选疫苗的效力，并定量由它们诱导的中和抗体，开发了一种基于2联Luminex的竞争性免疫测定法。与已发表的论文不同，无生物素偶联的中和单克隆抗体掺入的正常人血清（NHS）用于标准曲线制备，而藻红蛋白（PE）并未直接标记为中和单克隆抗体用于信号传导。在VLP与微球的偶联优化和中和mAb的生物素化之后，制备了具有良好拟合度和高动态范围的2重标准曲线。另外，也未确认到交叉反应。基于2联Luminex的免疫测定法不仅对候选疫苗的评估而且在其进一步的临床应用中都具有良好的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号